First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus
Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)
DOI: 10.1128/aac.01615-23 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Xiao-Jian Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Atea Pharmaceuticals Inc, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Dengue, Guanine Nucleotides, Prodrugs. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Atea Pharmaceuticals.
Abstract (Originalsprache)
AT-752 is a novel guanosine nucleotide prodrug inhibitor of the dengue virus (DENV) polymerase with sub-micromolar, pan-serotype antiviral activity. This phase 1, double-blind, placebo-controlled, first-in-human study evaluated the safety, tolerability, and pharmacokinetics of ascending single and multiple oral doses of AT-752 in healthy subjects. AT-752 was well tolerated when administered as a single dose up to 1,500 mg or when administered as multiple doses up to 750 mg three times daily (TID). No serious adverse events occurred, and the majority of treatment-emergent adverse events were mild in severity and resolved by the end of the study. In those receiving single ascending doses of AT-752, no pharmacokinetic sensitivity was observed in Asian subjects, and no food effect was observed. Plasma exposure of the guanosine nucleoside metabolite AT-273, the surrogate of the active triphosphate metabolite of the drug, increased with increasing dose levels of AT-752 and exhibited a long half-life of approximately 15–25 h. Administration of AT-752 750 mg TID led to a rapid increase in plasma levels of AT-273 exceeding the target in vitro 90% effective concentration (EC 90 ) of 0.64 µM in inhibiting DENV replication, and maintained this level over the treatment period. The favorable safety and pharmacokinetic results support the evaluation of AT-752 as an antiviral for the treatment of dengue in future clinical studies. Registered at ClinicalTrials.gov ( NCT04722627 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Atea Pharmaceuticals Inc, Boston, Massachusetts, USA.
- Nucleus Network, Melbourne, Australia.
ORCID-Profile: Xiao-Jian Zhou
Förderung
- Atea Pharmaceuticals
Zitieren
APA
Zhou, X. J., Lickliter, J., Montrond, M., Ishak, L., Pietropaolo, K., James, D., Belanger, B., Horga, A., & Hammond, J. (2024). First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.01615-23
Vancouver
Zhou XJ, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D, et al. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.01615-23
BibTeX
@article{Zhou2024,
author = {Zhou, Xiao-Jian and Lickliter, Jason and Montrond, Maureen and Ishak, Laura and Pietropaolo, Keith and James, Dayle and Belanger, Bruce and Horga, Arantxa and Hammond, Janet},
title = {First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {5},
doi = {10.1128/aac.01615-23}
}
EUVIMED